Literature DB >> 23635385

The role of bacterial biofilms in chronic infections.

Thomas Bjarnsholt1.   

Abstract

Acute infections caused by pathogenic bacteria have been studied extensively for well over 100 years. These infections killed millions of people in previous centuries, but they have been combated effectively by the development of modern vaccines, antibiotics and infection control measures. Most research into bacterial pathogenesis has focused on acute infections, but these diseases have now been supplemented by a new category of chronic infections caused by bacteria growing in slime-enclosed aggregates known as biofilms. Biofilm infections, such as pneumonia in cystic fibrosis patients, chronic wounds, chronic otitis media and implant- and catheter-associated infections, affect millions of people in the developed world each year and many deaths occur as a consequence. In general, bacteria have two life forms during growth and proliferation. In one form, the bacteria exist as single, independent cells (planktonic) whereas in the other form, bacteria are organized into sessile aggregates. The latter form is commonly referred to as the biofilm growth phenotype. Acute infections are assumed to involve planktonic bacteria, which are generally treatable with antibiotics, although successful treatment depends on accurate and fast diagnosis. However, in cases where the bacteria succeed in forming a biofilm within the human host, the infection often turns out to be untreatable and will develop into a chronic state. The important hallmarks of chronic biofilm-based infections are extreme resistance to antibiotics and many other conventional antimicrobial agents, and an extreme capacity for evading the host defences. In this thesis, I will assemble the current knowledge on biofilms with an emphasis on chronic infections, guidelines for diagnosis and treatment of these infections, before relating this to my previous research into the area of biofilms. I will present evidence to support a view that the biofilm lifestyle dominates chronic bacterial infections, where bacterial aggregation is the default mode, and that subsequent biofilm development progresses by adaptation to nutritional and environmental conditions. I will make a series of correlations to highlight the most important aspects of biofilms from my perspective, and to determine what can be deduced from the past decades of biofilm research. I will try to bridge in vitro and in vivo research and propose methods for studying biofilms based on this knowledge. I will compare how bacterial biofilms exist in stable ecological habitats and opportunistically in unstable ecological habitats, such as infections. Bacteria have a similar lifestyle (the biofilm) in both habitats, but the fight for survival and supremacy is different. On the basis of this comparison, I will hypothesize how chronic biofilm infections are initiated and how bacteria live together in these infections. Finally, I will discuss different aspects of biofilm infection diagnosis. Hopefully, this survey of current knowledge and my proposed guidelines will provide the basis and inspiration for more research, improved diagnostics, and treatments for well-known biofilm infections and any that may be identified in the future.
© 2013 APMIS Published by Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23635385     DOI: 10.1111/apm.12099

Source DB:  PubMed          Journal:  APMIS Suppl        ISSN: 0903-465X


  204 in total

1.  Characterization, the Antioxidant and Antimicrobial Activity of Exopolysaccharide Isolated from Poultry Origin Lactobacilli.

Authors:  Muhammad Shahid Riaz Rajoka; Hafiza Mahreen Mehwish; Hafiz Fakhar Hayat; Nazim Hussain; Sobia Sarwar; Humaira Aslam; Ahmad Nadeem; Junling Shi
Journal:  Probiotics Antimicrob Proteins       Date:  2019-12       Impact factor: 4.609

2.  Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.

Authors:  Trent Kunkle; Sanofar Abdeen; Nilshad Salim; Anne-Marie Ray; Mckayla Stevens; Andrew J Ambrose; José Victorino; Yangshin Park; Quyen Q Hoang; Eli Chapman; Steven M Johnson
Journal:  J Med Chem       Date:  2018-11-15       Impact factor: 7.446

3.  Upregulation of virulence genes promotes Vibrio cholerae biofilm hyperinfectivity.

Authors:  A L Gallego-Hernandez; W H DePas; J H Park; J K Teschler; R Hartmann; H Jeckel; K Drescher; S Beyhan; D K Newman; F H Yildiz
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-30       Impact factor: 11.205

4.  Topical Antimicrobials in Burn Care: Part 1-Topical Antiseptics.

Authors:  Janos Cambiaso-Daniel; Stafanos Boukovalas; Genevieve H Bitz; Ludwik K Branski; David N Herndon; Derek M Culnan
Journal:  Ann Plast Surg       Date:  2018-01-09       Impact factor: 1.539

5.  A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections.

Authors:  Yan Q Xiong; Angeles Estellés; L Li; W Abdelhady; R Gonzales; Arnold S Bayer; Edgar Tenorio; Anton Leighton; Stefan Ryser; Lawrence M Kauvar
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

6.  Natural products as inspiration for the development of bacterial antibiofilm agents.

Authors:  Roberta J Melander; Akash K Basak; Christian Melander
Journal:  Nat Prod Rep       Date:  2020-07-01       Impact factor: 13.423

7.  Evaluation of Peptide-Based Probes toward In Vivo Diagnostic Imaging of Bacterial Biofilm-Associated Infections.

Authors:  Landon W Locke; Kothandaraman Shankaran; Li Gong; Paul Stoodley; Samuel L Vozar; Sara L Cole; Michael F Tweedle; Daniel J Wozniak
Journal:  ACS Infect Dis       Date:  2020-07-14       Impact factor: 5.084

8.  Mixed-species biofilm compromises wound healing by disrupting epidermal barrier function.

Authors:  Sashwati Roy; Haytham Elgharably; Mithun Sinha; Kasturi Ganesh; Sarah Chaney; Ethan Mann; Christina Miller; Savita Khanna; Valerie K Bergdall; Heather M Powell; Charles H Cook; Gayle M Gordillo; Daniel J Wozniak; Chandan K Sen
Journal:  J Pathol       Date:  2014-05-27       Impact factor: 7.996

9.  Prevention of ESKAPE pathogen biofilm formation by antimicrobial peptides WLBU2 and LL37.

Authors:  Qiao Lin; Berthony Deslouches; Ronald C Montelaro; Y Peter Di
Journal:  Int J Antimicrob Agents       Date:  2018-05-10       Impact factor: 5.283

10.  In Vivo Gentamicin Susceptibility Test for Prevention of Bacterial Biofilms in Bone Tissue and on Implants.

Authors:  Louise Kruse Jensen; Thomas Bjarnsholt; Kasper N Kragh; Bent Aalbæk; Nicole Lind Henriksen; Sophie Amalie Blirup; Karen Pankoke; Andreas Petersen; Henrik Elvang Jensen
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.